ライフサイエンスコーパス: leiomyoma

1 nsurgical therapeutic strategies for uterine leiomyoma.

2 ently in leiomyosarcomas and not detected in leiomyoma.

3 ed in malignant myeloid diseases and uterine leiomyoma.

4 olymorphism was also found in one intramural leiomyoma.

5 may be used to facilitate extraction of the leiomyoma.

6 lipoleiomyoma is a rare and specific type of leiomyoma.

7 dupAAA mutation in the FH gene had cutaneous leiomyoma.

8 s, liver cysts, thyroid nodules, and uterine leiomyomas.

9 n with cutaneous leiomyomas also had uterine leiomyomas.

10 utations in FH in 35 families with cutaneous leiomyomas.

11 ividuals (47 women and 34 men) had cutaneous leiomyomas.

12 al myometria, was expressed in 16 of 19 Eker leiomyomas.

13 leiomyoma volume and location, and number of leiomyomas.

14 ndrome called multiple cutaneous and uterine leiomyomas.

15 d family with multiple cutaneous and uterine leiomyomas.

16 easured in 20 patients who underwent UAE for leiomyomas.

17 uent in leiomyosarcomas and absent in benign leiomyomas.

18 sting a role for this gene in the genesis of leiomyomas.

19 for chromosome 10 was not found in 13 benign leiomyomas.

20 ressure, sensation of mass), or both, due to leiomyomas.

21 esting a pathogenesis in common with uterine leiomyomas.

22 MR) evaluation of known or suspected uterine leiomyomas.

23 ility, which is frequently observed in human leiomyomas.

24 HIFU is used clinically in the treatment of leiomyomas.

25 ssion of versican in human LMS versus benign leiomyomas.

26 and HMGA2-overexpressing (HMGA2-LM) uterine leiomyomas.

27 ogesterone, leading to the growth of uterine leiomyomas.

28 ling chromothripsis were a common feature of leiomyomas.

29 ely common hormone-responsive tumor, uterine leiomyoma, a tumor with a significant impact on women's

30 Formation of new leiomyomas after these conservative therapies remains a

31 ight percent (46/47) of women with cutaneous leiomyomas also had uterine leiomyomas.

32 INGS: LMSP comprised approximately 1% of all leiomyoma and 2% of all myometrium-derived cells.

33 e effects of endogenous estrogens on uterine leiomyoma and may contribute to a complex hormonal milie

34 heparin were equally effective at inhibiting leiomyoma and myometrial smooth muscle cell proliferatio

35 HMGA1 was expressed in both leiomyoma and normal myometria.

36 ng activity in protein extracts from uterine leiomyoma and normal myometrium tissues.

37 in the development of cutaneous and uterine leiomyoma and renal cell cancer in this syndrome.

38 y, we conducted transcriptional profiling of leiomyoma and unaffected myometrium from humans and Eker

39 osomal dominant pattern, manifesting as skin leiomyoma and uterine fibroids in affected individuals.

40 No mutant bands were found in 3 leiomyomas and 11 leiomyosarcomas.

41 There were no mutations in 3 leiomyomas and 4 leiomyosarcomas.

42 We investigated 94 leiomyomas and 60 corresponding myometrial tissues using

43 are at risk to develop cutaneous and uterine leiomyomas and an aggressive form of kidney cancer.

44 the minimal region deleted in 10% of uterine leiomyomas and in 10-20% of acute myeloid leukemias and

45 es thermocoagulation and necrosis in uterine leiomyomas and is feasible and safe, without serious con

46 cally and immunohistochemically from typical leiomyomas and leiomyosarcomas.

47 ive therapy in the management of symptomatic leiomyomas and may prove to be a valuable alternative to

48 te dehydrogenase have been linked to uterine leiomyomas and paragangliomas, and cancer cells have bee

49 ne mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutati

50 genetic abnormalities in leiomyosarcomas or leiomyomas and surveyed chromosomes 7, 9, 10, 11, 12, 14

51 tic locus for multiple cutaneous and uterine leiomyomas and the availability of an extended multigene

52 and gene-expression profiling of 38 uterine leiomyomas and the corresponding myometrium from 30 wome

53 ew, noninvasive treatment method for uterine leiomyomas and to present a comparison with other curren

54 Leiomyomas and tumor-derived cells isolated from a rat m

55 luded subendometrial cysts, nabothian cysts, leiomyoma, and adenomyosis.

56 esenchymal submucosal tumors such as lipoma, leiomyoma, and gastrointestinal stromal tumors.

57 They were examined for cancer, polyp, leiomyoma, and hyperplasia.

58 be indicated for treatment of endometriosis, leiomyomas, and benign prostatic hyperplasia.

59 esenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas.

60 As leiomyomas are a hyperproliferation of smooth muscle cel

61 Uterine leiomyomas are benign but affect the health of millions

62 Uterine leiomyomas are benign tumors that can cause pain, bleedi

63 Uterine leiomyomas are common benign smooth muscle tumors that i

64 Uterine leiomyomas are extremely common estrogen and progesteron

65 Multiple cutaneous and uterine leiomyomas are inherited as an autosomal dominant trait,

66 Uterine leiomyomas are reported to be the most common benign gyn

67 Uterine fibroids (leiomyomas) are a major women's health problem.

68 Uterine fibroids (leiomyomas) are the most common tumors of the female rep

69 Leiomyomas arise from smooth muscle cells of the uterine

70 hown to cause multiple cutaneous and uterine leiomyomas as well as hereditary leiomyomatosis and rena

71 evaluate the role of HIFU in the therapy of leiomyomas as well as to review the actual clinical acti

72 The authors investigated the risk of uterine leiomyoma associated with exposure to 2,3,7,8,-tetrachlo

73 th a large indication range for all sizes of leiomyomas, associated with high efficacy, low operative

74 ther, our results show that the common human leiomyoma-associated MED12 variant can cause leiomyomas

75 on described as multiple well-differentiated leiomyomas at sites distant from the uterus.

76 Clinical research on HIFU therapy for leiomyomas began in the 1990s, and the majority of patie

77 diagnosis of pulmonary benign metastasizing leiomyoma being stated.

78 case each of sperm granuloma, spermatic cord leiomyoma, benign inflammatory nodule, and fibroma.

79 Benign metastasizing leiomyoma (BML) is a rare condition described as multipl

80 previously reported MED12 lesions in uterine leiomyoma but not those of other tumors.

81 alignant uterine leiomyosarcomas from benign leiomyomas by morphological criteria is not always possi

82 erials from 16 leiomyosarcomas and 13 benign leiomyomas by polymerase chain reaction for 26 microsate

83 d ultrasound surgery in treatment of uterine leiomyomas by using two treatment protocols.

84 Cutaneous leiomyomas can be associated with severe paroxysmal pain

85 Simvastatin potently stimulated leiomyoma cell apoptosis in a manner mechanistically dep

86 ty of the antiestrogen tamoxifen to modulate leiomyoma cell growth.

87 ession, whereas knockdown of KLF11 increased leiomyoma cell proliferation and abolished the antiproli

88 h muscle cell; however, it is not known what leiomyoma cell type is responsible for tumor growth.

89 le in determining whether TSC2-null Elt3 rat leiomyoma cells apoptose in response to UPR induction by

90 in pathway that enables mature myometrial or leiomyoma cells to send mitogenic signals to neighboring

91 ing that the levels of IGF-I produced by the leiomyoma cells were physiologically significant.

92 ll factor 4 in LMSP cells, but not in mature leiomyoma cells, blocked the estrogen/progesterone-depen

93 eptor (ER) signaling pathways were intact in leiomyoma cells, in addition to growth inhibition, stimu

94 IGF-I autocrine loop in tamoxifen-sensitive leiomyoma cells, supporting the hypothesis that the pres

95 rone stimulates the proliferation of uterine leiomyoma cells, the mechanism of progesterone action is

96 ing that this growth factor is mitogenic for leiomyoma cells.

97 vastatin inhibits the proliferation of human leiomyoma cells.

98 oliferation specifically in cultured primary leiomyoma cells.

99 ne receptor levels than mature myometrial or leiomyoma cells.

100 olving LMSP and differentiated myometrial or leiomyoma cells.

101 d be seeded from a single lineage of uterine leiomyoma cells.

102 of PR signaling and proliferation in uterine leiomyoma cells.

103 articipants 18 years or older with cutaneous leiomyomas characterized by pain at least once weekly an

104 In vitro experiments with a leiomyoma-derived cell line demonstrated that the pan-PP

105 o inhibit the proliferation of three of five leiomyoma-derived cell lines (ELT cell lines) in vitro,

106 A2 locus in either primary rat leiomyomas or leiomyoma-derived cell lines that expressed HMGA2.

107 All LMSP and leiomyoma-derived main population (LMMP) but none of the

108 cell-enriched population, designated as the leiomyoma-derived side population (LMSP), is responsible

109 ouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2

110 Well-perfused leiomyomas did not show greater volume reduction than th

111 a previous or coincident history of uterine leiomyoma, especially when no evidence of other malignan

112 ysregulated mTOR signaling as a component of leiomyoma etiology across species and directly show the

113 ve trial performed in the context of uterine leiomyoma evaluation.

114 Eker leiomyomas exhibited a 50% incidence of loss of the wild

115 Uterine leiomyomas (fibroids or myomas), benign tumours of the h

116 that this alteration alone promotes uterine leiomyoma formation and hyperplasia in both WT mice and

117 eratively and it is important to distinguish leiomyomas from other tumors for prevention from superer

118 Uterine myometria and spontaneous leiomyomas from the Eker rat, which carries a germ-line

119 tic locus for multiple cutaneous and uterine leiomyomas, from 14 cM to an interval of 4.55 or 7.19 cM

120 The ability of tamoxifen to decrease leiomyoma growth was found to correlate with expression

121 (41/46) of women with cutaneous and uterine leiomyomas had a total hysterectomy, 44% at age < or =30

122 aratesticular tumours can be benign (lipoma, leiomyoma, haemangioma) or malignant (rhabdomyosarcoma,

123 e explored transcriptional differences among leiomyomas harboring different genetic drivers, includin

124 plex cytogenetic abnormalities; in contrast, leiomyomas have simple or no cytogenetic abnormalities.

125 Uterine fibroids (leiomyomas) have historically been viewed as important c

126 exon 2 variants are associated with uterine leiomyomas; however, the causality of MED12 variants, th

127 nds (ME(90)) after injection of the dominant leiomyoma immediately after embolization was correlated

128 s c-kit (+) stromal tumor in 14 patients and leiomyoma in 2 patients.

129 ent a case of pulmonary benign metastasizing leiomyoma in a female patient admitted to our hospital w

130 leiomyoma-associated MED12 variant can cause leiomyomas in mice via a gain of function that drives ge

131 ition characterized by formation of multiple leiomyomas in the abdominal and pelvic peritoneum.

132 trial polyps were seen in 46 (47%) patients; leiomyoma, in 11 (11%); cancer, in four (4%); hyperplasi

133 E correlates with clinical response, whereas leiomyomas initially high in SI on T2-weighted images in

134 Leiomyomas initially high in SI on T2-weighted images sh

135 Pulmonary benign metastasizing leiomyoma is a rare entity.

136 Uterine leiomyoma is an estrogen-responsive tumor, and the prese

137 SERM) for the potential treatment of uterine leiomyoma is described.

138 Uterine leiomyoma is the most common benign tumor in reproductiv

139 Uterine leiomyoma is the most common tumor of the female genital

140 Each leiomyoma is thought to arise from a single mutated myom

141 Each leiomyoma is thought to be a benign monoclonal tumor ari

142 Medical management of painful cutaneous leiomyomas is generally unsatisfactory.

143 uided focused ultrasound surgery for uterine leiomyomas is reported.

144 Myomectomy, the excision of uterine leiomyoma, is now commonly performed via minimally invas

145 l Med12-KO mice resulted in earlier onset of leiomyoma lesions that were also greater in size.

146 thout exclusion of other mesenchymal tumors (leiomyoma, lipoma, gastrointestinal stromal tumor, leiom

147 ulated proliferation of mesenchymal cells in leiomyomas, lipomas, hamartomas,and other diseases has b

148 studies have identified subtypes of uterine leiomyoma (LM) with distinctive genetic alterations.

149 nt at 3 months were higher with a submucosal leiomyoma location (P =.04); however, this association w

150 A submucosal leiomyoma location was associated with a greater volume

151 Immediate reduction in leiomyoma ME(90) correlated with clinical response (Spea

152 Initial leiomyoma ME(90) was lower (P <.001), but it suppressed

153 vus (n = 1; 3%), hemorrhage (n = 1; 3%), and leiomyoma (n = 1; 3%).

154 neralized lymphoproliferative disorder and a leiomyoma of the liver a year later.

155 gland (1), surgical wound inflammation (2), leiomyoma of the uterus (1), suture granuloma (1), and e

156 ved at the HMGA2 locus in either primary rat leiomyomas or leiomyoma-derived cell lines that expresse

157 ene mutations were found in gastrointestinal leiomyomas or leiomyosarcomas.

158 Uterine leiomyomas (or fibroids) are the most common tumors in w

159 As a basis for understanding leiomyoma pathogenesis and identifying targets for pharm

160 Immediate reduction in leiomyoma perfusion after bilateral UAE correlates with

161 myometrial perfusion returned to normal, but leiomyoma perfusion remained suppressed (P <.001).

162 These results suggest that in uterine leiomyomas PPARgamma activation is growth inhibitory and

163 Cutaneous leiomyomas, rare benign tumors originating from the arre

164 Six leiomyomas received full therapeutic doses, and 98.5% of

165 200,000 procedures annually, the etiology of leiomyoma remains largely unknown.

166 cancer, Birt-Hogg-Dube syndrome, hereditary leiomyoma renal cell carcinoma, familial renal oncocytom

167 zes the need for molecular stratification in leiomyoma research and possibly in clinical practice as

168 Microarray analyses of 80 LMSs and 24 leiomyomas showed a significant elevated expression of v

169 Leiomyoma side-population (LMSP) cells comprising 1% of

170 Smaller baseline leiomyoma size and submucosal location are more likely t

171 Using matched pairs of human myometrial and leiomyoma smooth muscle cells from the same uterus, we d

172 eceptor (PR) target genes in primary uterine leiomyoma smooth muscle cells.

173 Expression of HMGI(Y) protein in this leiomyoma specimen is increased dramatically as compared

174 This report describes a uterine leiomyoma specimen with an inv(6)(p21q15).

175 estradiol and progesterone on these uterine leiomyoma subtypes emphasize the importance of subtypes

176 cteristics of the two most prevalent uterine leiomyoma subtypes, MED12-mutant (MED12-LM) and HMGA2-ov

177 y was driven by progesterone in both uterine leiomyoma subtypes.

178 consistent with a role in the initiation of leiomyoma, such as translocations of the HMGA2 and RAD51

179 ecurrent and mutually exclusive mutations in leiomyomas, suggesting the involvement of molecularly di

180 aggressive cancer; its common occurrence in leiomyomas suggests that it also has a role in the genes

181 predispose to multiple cutaneous and uterine leiomyoma syndrome (MCL) and MCL associated with renal c

182 KLF11 expression was significantly lower in leiomyoma tissues compared with adjacent myometrial tiss

183 6, which remained constitutively elevated in leiomyoma tissues.

184 ne of 56 mesenchymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusivel

185 In vitro studies have shown that uterine leiomyoma (UL) cells proliferate in response to IGF-I an

186 een in benign smooth muscle tumor as uterine leiomyoma (UL).

187 on well-differentiated benign lesions called leiomyomas (ULM), and rare, highly aggressive and pleomo

188 A global comparison of mRNA from leiomyoma versus myometrium in human and rat identified

189 eters were baseline uterine volume, baseline leiomyoma volume and location, and number of leiomyomas.

190 lk-related symptoms were not associated with leiomyoma volume change or location.

191 ession models indicated that larger dominant leiomyoma volume was associated with a smaller percentag

192 f botulinum toxin to treat painful cutaneous leiomyomas was associated with improved quality of life

193 tumor-suppressor gene predisposed to uterine leiomyomas, we show that an early-life exposure to dieth

194 ause of chromosomal abnormalities in uterine leiomyomas; we propose that tumorigenesis occurs when ti

195 Approximately 90% of cells in HMGA2-uterine leiomyoma were smooth muscle cells (SMC) with HMGA2 over

196 Human leiomyomas were also found to express all three PPAR iso

197 informed consent, patients with symptomatic leiomyomas were consecutively enrolled and treated at on

198 Studies addressing HIFU in leiomyomas were identified from a search of the Internet

199 Forty-five leiomyomas were noted (mean, four per patient).

200 the 1990s, and the majority of patients with leiomyomas were treated predominantly with HIFUNIT 9000

201 FH-deficient leiomyomas were uniquely characterized by activation of

202 leven children (17%) had leiomyosarcomas (or leiomyomas), which are otherwise exceptionally rare in c

203 sponsible for multiple cutaneous and uterine leiomyomas, which, in turn, may provide key information

204 y of solid tumors, including breast cancers, leiomyomas, Wilms' tumors, rhabdomyosarcomas, liposarcom

205 power morcellation, or fragmentation of the leiomyoma with a mechanical device, may be used to facil

206 he initial diagnosis of benign metastasizing leiomyoma with no evidence of neoplastic cells within th

207 Leiomyomas with HMGA2 aberrations displayed highly signi

208 esulting in expression signatures as seen in leiomyomas with HMGA2 aberrations.

209 tic locus for multiple cutaneous and uterine leiomyomas, with a maximum two-point LOD score of 4.453

210 HMGI(Y) expression was also found in 8 of 16 leiomyomas without cytogenetically detectable chromosome

211 ristics, are necessary for in vivo growth of leiomyoma xenograft tumors.